Aurinia Pharm Ord (AUPH) Stock Price, Quote & News

Company Profile

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was fou...

Industry: Biotechnology

Sector: Healthcare

Phone: 250 744 2487

Fax: 250 708 4345

Website: www.auriniapharma.com

Address:

#140, 14315 – 118 Avenue, Edmonton, Canada

PivotGuardian Apr. 30 at 7:37 AM

$SENS $DKNG $RAYA $MNTS $AUPH Medical devices, online betting, speculative names, transportation tech, and biotech catalysts complete a high-volatility basket driven by both innovation and sentiment.

0 · Reply

IDrinkandKnowThings Apr. 30 at 12:52 AM

$AUPH So what's the scoop? What c ame of the generics Court hearing? Anyone?

0 · Reply

NatasKapus Apr. 30 at 12:14 AM

$AUPH what if this is a giant 8 year severely disfigured cup and handle? Haha doesn’t hurt to dream

0 · Reply

Thelonius_Stonk Apr. 29 at 11:59 PM

$AUPH sorry guys i broke it. watch for the make em panic sell candle

1 · Reply

santabarbarabob Apr. 29 at 10:53 PM

$AUPH Bios don’t do well in an inflationary environment especially since the Fed stated today that they had an unusual amount of board members who wanted to raise rates. Bios feast on raising cash for R&D. Fortunately, AUPH has zero need to raise cash but the stock gets hammered because it’s in the various Bio ETFs…….

0 · Reply

tothebeach Apr. 29 at 10:46 PM

$AUPH

0 · Reply

Yarrow Apr. 29 at 10:08 PM

$AUPH 👇 To be fair, if I wouldve bought Auph last.May I wouldve doubled also.🤪

0 · Reply

Yarrow Apr. 29 at 10:01 PM

$AUPH Bought google last May for $160. and have been begging Pete for a sale on this crap for 8 years.

1 · Reply

Hopenitsgood Apr. 29 at 10:01 PM

$AUPH Yep.... fake orange juice....

0 · Reply

RicardoDelJuego Apr. 29 at 9:26 PM

$AUPH Perhaps worth noting too that Hikma and a co-defendant reached a settlement with Pfizer in an infringement case of a similar vein to ours yesterday: https://www.law360.com/articles/2470423/hikma-cipla-cut-deals-in-pfizer-heart-drug-patent-case Hopefully we'll see one for our case ASAP too.

1 · Reply

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

KZR

Mar 23, 2026, 11:00 AM EDT - 5 weeks ago

MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition

Mar 23, 2026, 10:26 AM EDT - 5 weeks ago

Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning

Mar 23, 2026, 8:00 AM EDT - 5 weeks ago

Aurinia Announces Management Transition

Feb 26, 2026, 4:06 PM EST - 2 months ago

Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets

Feb 26, 2026, 8:30 AM EST - 2 months ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 6:00 AM EST - 2 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

Feb 19, 2026, 6:00 AM EST - 2 months ago

Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026

Nov 4, 2025, 8:30 AM EST - 6 months ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 6:00 AM EST - 6 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress

Nov 3, 2025, 6:00 AM EST - 6 months ago

Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025

Oct 15, 2025, 6:00 AM EDT - 7 months ago

Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025

Sep 29, 2025, 8:27 PM EDT - 7 months ago

Aurinia Responds to Now Retracted LinkedIn Post

Jul 31, 2025, 8:30 AM EDT - 9 months ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q2 2025

Jul 31, 2025, 6:00 AM EDT - 9 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025

Jul 22, 2025, 6:00 AM EDT - 10 months ago

Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025

Jun 30, 2025, 8:30 AM EDT - 10 months ago

Aurinia Pharmaceuticals Transcript: Study Result

Jun 30, 2025, 6:00 AM EDT - 10 months ago

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

Jun 29, 2025, 5:00 PM EDT - 10 months ago

Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025

May 22, 2025, 6:00 AM EDT - 1 year ago

New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

May 12, 2025, 12:56 PM EDT - 1 year ago

Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance

May 12, 2025, 8:30 AM EDT - 1 year ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q1 2025

May 12, 2025, 6:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

May 5, 2025, 6:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

Apr 30, 2025, 6:00 AM EDT - 1 year ago

Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

Apr 29, 2025, 6:00 AM EDT - 1 year ago

ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting

Feb 27, 2025, 2:11 PM EST - 1 year ago

Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations

Feb 27, 2025, 8:30 AM EST - 1 year ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 27, 2025, 6:00 AM EST - 1 year ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

Feb 20, 2025, 4:05 PM EST - 1 year ago

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Nov 18, 2024, 5:53 PM EST - 1 year ago

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Nov 15, 2024, 6:00 AM EST - 1 year ago

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Nov 14, 2024, 6:00 AM EST - 1 year ago

Aurinia to Participate in Jefferies London Healthcare Conference

Nov 7, 2024, 8:30 AM EST - 1 year ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 6:10 AM EST - 1 year ago

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

Nov 7, 2024, 6:00 AM EST - 1 year ago

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

Oct 30, 2024, 4:05 PM EDT - 1 year ago

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024

Oct 11, 2024, 6:00 AM EDT - 1 year ago

Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024

Sep 24, 2024, 8:10 AM EDT - 1 year ago

Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis

Sep 17, 2024, 3:05 PM EDT - 1 year ago

Aurinia Pharmaceuticals Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 13, 2024, 6:00 AM EDT - 1 year ago

Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Aurinia Announces Board Restructuring

Sep 5, 2024, 6:00 AM EDT - 1 year ago

Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial

Aug 28, 2024, 6:00 AM EDT - 1 year ago

Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board

Aug 1, 2024, 8:30 AM EDT - 1 year ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 1, 2024, 6:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results

Jul 19, 2024, 6:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024

Jul 11, 2024, 3:27 PM EDT - 1 year ago

ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders' Voices Expressed at the AGM

Jul 2, 2024, 6:00 AM EDT - 1 year ago

Aurinia to Participate in Upcoming Investor Healthcare Conferences

Jun 14, 2024, 12:16 PM EDT - 2 years ago

Aurinia Announces 2024 Annual General Meeting Results

Jun 5, 2024, 8:25 AM EDT - 2 years ago

Aurinia Pharmaceuticals Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 6:00 AM EDT - 2 years ago

Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024

Jun 4, 2024, 5:30 PM EDT - 2 years ago

Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce

Jun 3, 2024, 6:30 PM EDT - 2 years ago

Aurinia Provides Update on Proxy Statement

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Aurinia Pharmaceuticals Shareholder Urges Fellow Shareholders to Withhold Support for CEO Peter Greenleaf

May 30, 2024, 6:00 AM EDT - 2 years ago

Aurinia Will Attend 2024 Jefferies Global Healthcare Conference

May 15, 2024, 10:00 AM EDT - 2 years ago

Aurinia Pharmaceuticals Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 14, 2024, 6:00 AM EDT - 2 years ago

Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024

May 9, 2024, 6:00 AM EDT - 2 years ago

Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024

May 2, 2024, 8:30 AM EDT - 2 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q1 2024

Mar 5, 2024, 1:30 PM EST - 2 years ago

Aurinia Pharmaceuticals Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 15, 2024, 8:30 AM EST - 2 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q4 2023

Nov 2, 2023, 8:30 AM EDT - 2 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q3 2023

Aug 3, 2023, 8:30 AM EDT - 2 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q2 2023

May 4, 2023, 8:30 AM EDT - 3 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q1 2023

Apr 5, 2023, 8:30 AM EDT - 3 years ago

Aurinia Pharmaceuticals Transcript: Study Result

Feb 28, 2023, 8:30 AM EST - 3 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q4 2022

Jan 11, 2023, 7:30 PM EST - 3 years ago

Aurinia Pharmaceuticals Transcript: JPMorgan Healthcare Conference

Nov 3, 2022, 9:30 AM EDT - 3 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q3 2022

Aug 3, 2022, 8:49 PM EDT - 4 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q2 2022

May 10, 2022, 8:21 AM EDT - 4 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q1 2022

Feb 28, 2022, 4:33 AM EST - 4 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q4 2021

Nov 2, 2021, 8:00 PM EDT - 4 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q3 2021

Aug 4, 2021, 8:00 PM EDT - 5 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q2 2021

Jun 7, 2021, 12:00 PM EDT - 5 years ago

Aurinia Pharmaceuticals Transcript: AGM 2021

May 6, 2021, 5:00 PM EDT - 5 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q1 2021

Feb 24, 2021, 4:30 PM EST - 5 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q4 2020

Jan 25, 2021, 8:30 AM EST - 5 years ago

Aurinia Pharmaceuticals Transcript: FDA Announcement

Nov 10, 2020, 4:30 PM EST - 5 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q3 2020

Nov 2, 2020, 4:30 PM EST - 5 years ago

Aurinia Pharmaceuticals Transcript: Study Update

Aug 11, 2020, 4:30 PM EDT - 6 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q2 2020

Jun 2, 2020, 12:00 PM EDT - 6 years ago

Aurinia Pharmaceuticals Transcript: AGM 2020

May 14, 2020, 4:30 PM EDT - 6 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q1 2020

Mar 26, 2020, 5:15 PM EDT - 6 years ago

Aurinia Pharmaceuticals Transcript: Study Update

Mar 5, 2020, 4:30 PM EST - 6 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q4 2019

Dec 5, 2019, 8:30 AM EST - 6 years ago

Aurinia Pharmaceuticals Transcript: Study Result

Nov 14, 2019, 4:30 PM EST - 7 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q3 2019

Aug 6, 2019, 4:30 PM EDT - 7 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q2 2019

May 14, 2019, 4:30 PM EDT - 7 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q1 2019

Mar 19, 2019, 4:30 PM EDT - 7 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q4 2018

Jan 22, 2019, 8:00 AM EST - 7 years ago

Aurinia Pharmaceuticals Transcript: Study Result

Nov 8, 2018, 4:30 PM EST - 8 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q3 2018

Aug 9, 2018, 4:30 PM EDT - 8 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q2 2018

May 10, 2018, 4:30 PM EDT - 8 years ago

Aurinia Pharmaceuticals Earnings Call Transcript: Q1 2018

PivotGuardian Apr. 30 at 7:37 AM

$SENS $DKNG $RAYA $MNTS $AUPH Medical devices, online betting, speculative names, transportation tech, and biotech catalysts complete a high-volatility basket driven by both innovation and sentiment.

0 · Reply

IDrinkandKnowThings Apr. 30 at 12:52 AM

$AUPH So what's the scoop? What c ame of the generics Court hearing? Anyone?

0 · Reply

NatasKapus Apr. 30 at 12:14 AM

$AUPH what if this is a giant 8 year severely disfigured cup and handle? Haha doesn’t hurt to dream

0 · Reply

Thelonius_Stonk Apr. 29 at 11:59 PM

$AUPH sorry guys i broke it. watch for the make em panic sell candle

1 · Reply

santabarbarabob Apr. 29 at 10:53 PM

0 · Reply

tothebeach Apr. 29 at 10:46 PM

$AUPH

0 · Reply

Yarrow Apr. 29 at 10:08 PM

$AUPH 👇 To be fair, if I wouldve bought Auph last.May I wouldve doubled also.🤪

0 · Reply

Yarrow Apr. 29 at 10:01 PM

$AUPH Bought google last May for $160. and have been begging Pete for a sale on this crap for 8 years.

1 · Reply

Hopenitsgood Apr. 29 at 10:01 PM

$AUPH Yep.... fake orange juice....

0 · Reply

RicardoDelJuego Apr. 29 at 9:26 PM

1 · Reply

Send_IT_or_stepaside Apr. 29 at 9:25 PM

$AUPH

0 · Reply

SCCT2FL Apr. 29 at 9:20 PM

$AUPH was the c-suite all previously monks sworn to a code of silence?

0 · Reply

Judge_Smails Apr. 29 at 9:05 PM

$AUPH latest opinion on Supreme Court: https://natlawreview.com/article/how-skinny-skinny-enough-takeaways-scotus-oral-argument-amarinhikma-case?amp

0 · Reply

Auphiliate Apr. 29 at 8:42 PM

$AUPH Is there a plan? 🧐

0 · Reply

ultistock Apr. 29 at 8:35 PM

$AUPH It is nearly impossible to actively run a pharmaceutical company and not have PR's occasionally, even just because they are legally mandated for some events. If we are going to get one before earnings, I would think tomorrow would be a good spot, because then next week it will be the earnings date announcement, and then after that everything else can wait until earnings...

1 · Reply

Hoganknowsbest Apr. 29 at 8:28 PM

$AUPH what is tang doing? It's been almost 2 months since he's been CEO and absolute radio silence from him and his new team. Where are updates for shareholders? I truly don't fucking get this stock.

4 · Reply

Hoganknowsbest Apr. 29 at 8:23 PM

$AUPH wow wtf. This thing never does shit.

0 · Reply

IDrinkandKnowThings Apr. 29 at 8:14 PM

$AUPH Well, that's Fucked! Guessing the generic bearing didn't go well?

0 · Reply

jdoldnumber7 Apr. 29 at 8:05 PM

$AUPH So much for afternoon rally!

0 · Reply

ATzmansto Apr. 29 at 8:03 PM

$AUPH Pathetic

0 · Reply

PatagoniaSweaterVest Apr. 29 at 6:00 PM

$AUPH sorry guys, bought more yesterday. Guess it’s time to load additional.

0 · Reply

Market Cap	2.08B
Revenue (ttm)	283.06M
Net Income (ttm)	287.20M
EPS (ttm)	N/A
PE Ratio	20.21
Forward PE	20.15
Profit Margin	101.46%
Debt to Equity Ratio	0.00

Volume	1,310,200
Avg Vol	1,127,068
Day's Range	N/A - N/A
Shares Out	129.94M
Stochastic %K	5%
Beta	1.51
Analysts	Sell
Price Target	$17.00